97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details
臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05372939 (ClinicalTrials.gov) | February 5, 2021 | 22/9/2021 | Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET) | A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory, Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Combination With Adalimumab in Subjects With Moderate to Severe Ulcerative Colitis | Ulcerative Colitis | Drug: AMT-101 (oral);Other: Placebo (oral);Combination Product: Humira (adalimumab) | Applied Molecular Transport | NULL | Completed | 18 Years | 75 Years | All | 51 | Phase 2 | Georgia;Netherlands;Poland;Ukraine |
| 2 | NCT04583358 (ClinicalTrials.gov) | August 26, 2020 | 16/9/2020 | Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD) | A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects With Moderate to Severe Ulcerative Colitis (LOMBARD) | Ulcerative Colitis | Drug: AMT-101 (oral);Other: Placebo (oral) | Applied Molecular Transport | NULL | Active, not recruiting | 18 Years | 80 Years | All | 105 | Phase 2 | United States;Belarus;Bulgaria;Canada;France;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Russian Federation;Switzerland;Ukraine;United Kingdom |